All Star Options Articles

Today's trade is in a name that specializes in 3D geolocation technology, offering positioning, navigation, and timing (PNT) solutions—especially in situations where traditional GPS fails.

And I think it's got all-time highs in it's sights.

Today I closed out a trade in $CRK that I opened back in mid-March — a September 22/30 Bull Call Spread I bought for $1.85.

The most that spread could have been worth on expiration day is $8.00. I closed it today for $5.40:

So naturally, the question is:

Why didn’t I hold out for more?

Simple: Time and risk.

There are still 93 days left until expiration. Yes, the stock is trading above my short strike, and yes, in theory this spread could still work its way up to full value.

But holding for that last $2.60 of potential upside means I’d be risking the $5.40 it’s worth today — a healthy open profit — for a maybe.

That’s not a tradeoff I like.

I know, I know — once both strikes are in the money, a debit spread becomes a positive theta position. Every day the stock stays above the short strike, a little more value seeps into the trade. I get that. But the key word is “a little.” Theta drip is slow and steady. The risk of a sharp reversal, especially after the run $CRK has just had, feels much more significant to me.

In other words:

I’d be risking...

The title for this post was too easy.

Today's trade is in a $29B ultra-processed packaged foods giant that has been struggling since 2023 and feels like its hanging on the precipice of a deeper fall.

Whether or not that comes to pass, this stock feels like a good place to put on a slightly bearish bet to give my bullish portfolio a bit of diversification in case the broader market stalls here.

Today's trade is in a name that has a very high short interest and is starting to put the squeeze on shorts. 

And if this stock completes its climb back to all-time highs, there will be a lot of juice to squeeze out of these shorts.

When my friend and client—who manages a three-commas portfolio—calls me with a trade idea, I listen.

Sure, he’s human like the rest of us. Prone to bias, emotion, and the occasional bad read. But over the years, he’s earned my respect. He’s sharp, curious, and often brings fresh perspective to the table. So when his name pops up on my phone, I answer.

This week, he rang me up to talk about a stock that’s down 95% from its highs.

I’ll be honest—where I come from, we call that dumpster diving.

But as he laid out his case, I started to lean in.

He noted signs of a likely turn in the broader sector. He pointed out a major price gap from ten months ago that, if filled, could offer serious upside. And he reminded me that the stock in question is a “story stock”—the kind momentum traders love to chase if the price action gives them the green light.

While we talked, I pulled up the options chain and started scanning out in time—way out.

I found a June 2026 call with a roughly 1-in-4 shot of landing in the money. But if we’re right and that gap fills? That option could return 30x.

Today's trade is in a stock that has been seemingly left for dead. Which is ironic, considering this company is engaged in keeping people alive.

This biotech company is an astounding 95% off it's 2021 highs.

But here's the thing... this stock just crossed above its 50-day moving average and appears to be holding there. And with a new leg higher in the stock market likely to lift a lot of boats, there is opportunity here.

Back in early April, I made a bet that silver would play catch-up to the vastly outperforming gold complex utilizing an options trader's version of a pairs trade. You can read about it here.

Both instruments had a bit of a wild ride following the "Liberation Day" Luau, especially SLV. But thanks to the somewhat offsetting risks of the short-biased GLD trade, we road out the volatility admirably.

Today, following SLV's recent run and dramatic outperformance against GLD, I think now is the time to take our profits.

Today's trade is in a silver miner that has already had a great run, but could surprise everyone by further doubling from here.

Buying after a big run is always hard, psychologically, and today is no different. So I'm going to take some of the sting out of the purchase with a creative spread and aggressive rolling strategy.

Back in October, I put on a bullish position in Cameco ($CCJ). It was a diagonal call calendar spread: I bought January 2026 $80 calls and sold December 2024 $65 calls against them, paying a net debit of $3.50.

The idea was pretty straightforward: I wanted to own the long-dated $80 calls, but I wanted them cheaper—so I financed them by selling front-month calls.

Had I done nothing after that—just sat on my hands—the short December calls would’ve expired worthless, and I’d still be holding the January 2026s. I’d be down about $1.25 on the trade today. Not ideal, but manageable.

But I didn’t do nothing.

As CCJ started to slide in November, I began actively managing the position. I rolled the short calls five separate times, each time pushing them out to a later month and collecting a bit more premium. Each roll chipped away at my initial cost basis:

By April 16, I had reduced my downside risk so much that the entire campaign had flipped into a 77-cent net credit!. If CCJ continued to go nowhere or down, all my options would eventually expire worthless and I’d actually walk away a small winner...

Today's trade is in a biotech stock. And the word "biotech" should cue thoughts of "risky" and "volatile."

And this trade is no exception. So I'm going to get creative, utilizing a spread to lower my cost of participation, define my risk, and give me two paths to profitability. 

One of the best parts about building a trading community isn’t just sharing my own ideas—it’s seeing others take those ideas and make them even better.

Case in point: Yesterday, I closed out a call calendar spread in $AVGO for a solid win. The trade worked—price moved up into my strikes, and I took the profit. Mission accomplished.

But then a member of my All Star Options community shared what he did instead… and honestly, it might’ve been the better play.

Here’s what he wrote:

“I couldn’t bring myself to fully exit AVGO given the price action and breakout over the December highs, so I closed the short position, paid for it by selling a portion of the longs, plus enough more to put me in free ride mode, guaranteeing a 30% gain. What remains is currently double the buy-in for the original spread…”

Brilliant.

Instead of just locking in the profit like I did, he saw continued momentum and structured a creative way to both guarantee a gain and keep a position on for more upside—all while removing his risk....

(IYKYK)

I love finding stocks that are under the radar, but are starting to get noticed, quietly. That's what my team's Under the Hood report uncovers, and today's trade comes from the most recent release.

We're getting involved early, before the masses catch on and send this stock back to yearly highs, which would be a nice ride from here.